Wall Street Zen Downgrades Oculis (NASDAQ:OCS) to Strong Sell

Oculis (NASDAQ:OCS) was downgraded by investment analysts at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Sunday.

Several other equities analysts also recently commented on OCS. Guggenheim lowered their price target on Oculis from $75.00 to $45.00 and set a “buy” rating on the stock in a report on Monday, June 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oculis in a report on Tuesday, April 21st. JPMorgan Chase & Co. lowered their target price on shares of Oculis from $42.00 to $23.00 and set an “overweight” rating on the stock in a research note on Wednesday, June 3rd. Needham & Company LLC lowered their target price on shares of Oculis from $46.00 to $38.00 and set a “buy” rating on the stock in a research note on Monday, June 1st. Finally, HC Wainwright reiterated a “buy” rating on shares of Oculis in a report on Thursday, June 11th. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $38.33.

Oculis Stock Down 0.5%

Shares of NASDAQ:OCS traded down $0.07 on Friday, reaching $13.63. The company had a trading volume of 201,538 shares, compared to its average volume of 491,565. The stock has a market capitalization of $790.27 million, a P/E ratio of -6.40 and a beta of 0.44. The stock has a 50-day moving average price of $19.19 and a 200 day moving average price of $23.63. Oculis has a twelve month low of $10.52 and a twelve month high of $34.47. The company has a quick ratio of 5.18, a current ratio of 5.18 and a debt-to-equity ratio of 0.01.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.63) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.14). Oculis had a negative net margin of 8,460.67% and a negative return on equity of 56.78%. The company had revenue of $0.26 million for the quarter, compared to analyst estimates of $0.25 million. On average, equities analysts expect that Oculis will post -2.27 EPS for the current year.

Institutional Trading of Oculis

Hedge funds have recently bought and sold shares of the stock. Gildi lifeyrissjodur acquired a new stake in Oculis in the 4th quarter worth $50,250,000. Aberdeen Group plc lifted its stake in shares of Oculis by 39.4% in the fourth quarter. Aberdeen Group plc now owns 1,746,946 shares of the company’s stock valued at $34,887,000 after buying an additional 493,827 shares during the period. Syquant Capital Sas acquired a new stake in Oculis during the fourth quarter worth about $3,849,000. Folketrygdfondet acquired a new stake in Oculis during the fourth quarter worth about $3,651,000. Finally, NEXTBio Capital Management LP bought a new position in Oculis during the fourth quarter valued at about $2,991,000. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.